Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

LXRX

Lexicon Pharmaceuticals Inc

Feb 13 • 04:00PM ET

1.31

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN BMRN INCY ALNY IONS NBIX KNSA ALLO

| Held by: VTI VXF SCHA PRFZ VHT SCHB QQQS BTEC

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	55.52%	Shs Outstand	363.40M	Perf Week	6.50%
Market Cap	518.06M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.71%	Shs Float	175.92M	Perf Month	5.65%
Enterprise Value	467.05M	PEG	-	EPS next Q	-0.07	Inst Own	22.85%	Short Float	13.97%	Perf Quarter	-14.94%
Income	-68.58M	P/S	7.31	EPS this Y	73.50%	Inst Trans	0.24%	Short Ratio	10.27	Perf Half Y	11.02%
Sales	70.86M	P/B	3.96	EPS next Y	-46.49%	ROA	-26.02%	Short Interest	24.58M	Perf YTD	13.91%
Book/sh	0.33	P/C	4.47	EPS next 5Y	28.96%	ROE	-45.92%	52W High	1.83 -28.42%	Perf Year	76.72%
Cash/sh	0.29	P/FCF	-	EPS past 3/5Y	-1.29% -	ROIC	-37.38%	52W Low	0.28 361.92%	Perf 3Y	-42.79%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	370.72% -37.35%	Gross Margin	98.52%	Volatility	6.71% 11.00%	Perf 5Y	-83.83%
Dividend TTM	-	EV/Sales	6.59	EPS Y/Y TTM	74.58%	Oper. Margin	-81.80%	ATR (14)	0.12	Perf 10Y	-85.18%
Dividend Ex-Date	-	Quick Ratio	5.63	Sales Y/Y TTM	1255.21%	Profit Margin	-96.77%	RSI (14)	49.38	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	5.64	EPS Q/Q	80.42%	SMA20	-5.72%	Beta	0.96	Target Price	2.92
Payout	-	Debt/Eq	0.54	Sales Q/Q	710.40%	SMA50	1.11%	Rel Volume	0.46	Prev Close	1.31
Employees	103	LT Debt/Eq	0.53	Earnings	Nov 06 BMO	SMA200	14.26%	Avg Volume	2.39M	Price	1.31
IPO	Apr 07, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	39.39% 205.04%	Trades		Volume	1,103,857	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-05-25	Downgrade	Leerink Partners	Outperform → Market Perform	$2 → $1
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26

Show Previous Ratings

Feb-06-26 05:17PM	Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-30-26 02:58PM	Citi Raises Lexicon Pharmaceuticals (LXRX) Outlook on Strength of Novo Nordisk Partnership Milestones (Insider Monkey) -19.44%
02:50AM	Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
Jan-29-26 04:31PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire)
07:05AM	Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Loading…
Jan-23-26 08:30AM	Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary (GlobeNewswire)
Jan-21-26 08:30AM	Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +19.08%
Jan-12-26 07:30AM	Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-09-26 08:30AM	Lexicon Pharmaceuticals Publishes "Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain" (GlobeNewswire)
Jan-07-26 08:30AM	Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-10-25 08:30AM	Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 (GlobeNewswire)
Dec-05-25 08:30AM	Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum (GlobeNewswire)
Nov-25-25 08:30AM	Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences (GlobeNewswire)
Nov-24-25 09:47AM	Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development (Insider Monkey) +5.97%
Nov-11-25 08:30AM	Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference (GlobeNewswire) +9.86%
02:30PM	Loading…
Nov-08-25 02:30PM	Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 (GlobeNewswire)
Nov-06-25 08:50AM	Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:47AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates (GlobeNewswire)
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 08:30AM	Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans (GlobeNewswire)
Oct-30-25 08:30AM	Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-14-25 08:00AM	Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit (GlobeNewswire)
Oct-08-25 07:59AM	Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain (GlobeNewswire) -5.92%
Sep-22-25 04:00PM	Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-17-25 07:00AM	Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings (GlobeNewswire)
Sep-11-25 08:30AM	Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings (GlobeNewswire)
Sep-08-25 08:30AM	Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista in Type 1 Diabetes (GlobeNewswire)
Sep-04-25 08:30AM	Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025 (GlobeNewswire)
Sep-03-25 08:30AM	Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 (GlobeNewswire)
08:30AM	Loading…
Sep-02-25 08:30AM	Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress (GlobeNewswire)
Aug-27-25 08:30AM	Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-08-25 12:00PM	Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-06-25 08:45AM	Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates (Zacks) +9.52%
07:47AM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-05-25 06:35PM	Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates (Zacks) -6.25%
Jul-31-25 08:00AM	Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Jul-23-25 08:00AM	Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-20-25 12:35AM	H.C. Wainwright Reiterates a Buy Rating on Lexicon Pharmaceuticals (LXRX) (Insider Monkey)
Jul-18-25 08:00AM	Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025) (GlobeNewswire) -8.89%
Jun-23-25 08:00AM	Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-18-25 08:30AM	Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA) (GlobeNewswire)
Jun-10-25 09:08AM	Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM (Zacks) -5.91%
Jun-06-25 11:52AM	KURA Stock Rises More Than 15% This Past Week: Here's Why (Zacks) +6.93%
11:35AM	TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy (Zacks)
Jun-05-25 01:03PM	Zoetis Stock Rises 13% in a Month: Time to Add to Your Portfolio? (Zacks) +8.46%
12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks)
Jun-04-25 12:17PM	JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer (Zacks)
10:46AM	SNY's Rilzabrutinib Wins 4th Orphan Drug Tag for Sickle Cell Disease (Zacks)
Jun-03-25 11:14AM	Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug (Zacks)
09:43AM	Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III (Zacks)
Jun-02-25 10:53AM	MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study (Zacks)
May-30-25 10:20AM	NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study (Zacks) -5.03%
08:59AM	IMVT Q4 Loss Narrower Than Expected, Stock Up, Pipeline in Focus (Zacks)
May-29-25 11:44AM	BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications (Zacks) -5.66%
10:50AM	CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer (Zacks)
08:00AM	Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-28-25 11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
11:07AM	TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate (Zacks)
10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks)
May-27-25 10:46AM	AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder Cancer (Zacks)
May-26-25 11:44AM	GSK Gets CHMP Nod for Blenrep Combos in Multiple Myeloma (Zacks)
11:25AM	SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease (Zacks)
May-21-25 11:19AM	Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential (Insider Monkey) +7.65%
May-19-25 08:00AM	SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology (GlobeNewswire)
May-15-25 10:00AM	ETFs to Capitalize on the Novo Nordisk-Septerna Deal (Zacks)
May-14-25 09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna (Yahoo Finance) -15.57%
09:32AM	Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna (Yahoo Finance)
03:18AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-13-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.51%
04:06PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:00PM	Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 04:30PM	Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire) -8.90%
08:00AM	Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 (GlobeNewswire)
Apr-29-25 02:29PM	Growth Is Priced Out Of Novo Nordisk (Seeking Alpha)
Apr-02-25 10:18AM	LXRX Stock Moves Up 30% in a Week: What is Driving This Rally? (Zacks) +8.40%
08:00AM	Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 06:10PM	Lexicon's Drug Discovery Engine Validated By Novo's $1 Billion Obesity Drug Deal (Upgrade) (Seeking Alpha) +64.13% -19.23%
04:17PM	Novo Nordisk Inks Its Second Big Obesity Deal In A Week And It's Not For A GLP-1 (Investor's Business Daily)
01:04PM	Novo Nordisk strikes $1bn deal for Lexicons oral obesity drug (Pharmaceutical Technology)
07:30AM	Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 (GlobeNewswire)
Mar-07-25 08:30AM	Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 (GlobeNewswire) +6.55%
02:17AM	Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Mar-06-25 05:10PM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +9.43%
04:18PM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-04-25 04:15PM	Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 (GlobeNewswire) +11.00%
Mar-03-25 07:00AM	Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire) -58.17%
Mar-02-25 04:13PM	Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain (GlobeNewswire)
Feb-18-25 08:00AM	Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) (GlobeNewswire)
Jan-21-25 08:00AM	Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain (GlobeNewswire) +14.25%
Jan-06-25 09:16AM	Heres Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10 (Insider Monkey) +15.94%
Jan-02-25 08:00AM	Lexicon Appoints Scott Coiante as Chief Financial Officer (GlobeNewswire) +5.23%
Dec-20-24 04:30PM	Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) (GlobeNewswire) +15.71%
Nov-27-24 07:30AM	Lexicon completes subject enrolment for DPNP trial of LX9211 (Clinical Trials Arena)
Nov-26-24 08:00AM	Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-25-24 04:15PM	Lexicon Pharmaceuticals to Participate in December Investor Conferences (GlobeNewswire) -5.81%

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Invus Global Management, LLC	Director	Feb 02 '26	Buy	1.30	1,538,462	2,000,001	1,538,462	Feb 04 04:25 PM
Swain Judith L	Director	May 13 '25	Option Exercise	0.00	36,810	0	85,174	May 13 05:52 PM
Sullivan Diane E.	Director	May 13 '25	Option Exercise	0.00	36,810	0	36,810	May 13 05:51 PM
SOBECKI CHRISTOPHER J	Director	May 13 '25	Option Exercise	0.00	36,810	0	203,865	May 13 05:50 PM
BARKER SAM L	Director	May 13 '25	Option Exercise	0.00	36,810	0	124,459	May 13 05:50 PM
Amouyal Philippe	Director	May 13 '25	Option Exercise	0.00	36,810	0	285,174	May 13 05:49 PM
DEBBANE RAYMOND	Director	May 13 '25	Option Exercise	0.00	36,810	0	1,385,689	May 13 05:48 PM

Open in Screener

WW

WW International Inc

Feb 13 • 04:00PM ET

23.22

+0.22 0.96 %

Consumer Cyclical • Personal Services • USA • NASD

WW WW International Inc daily Stock Chart

Held by: VXF EES DEEP RFLR AVSC

Index	-	P/E	0.21	EPS (ttm)	112.84	Insider Own	0.39%	Shs Outstand	9.99M	Perf Week	6.08%
Market Cap	231.90M	Forward P/E	-	EPS next Y	-	Insider Trans	275.92%	Shs Float	9.95M	Perf Month	-10.76%
Enterprise Value	523.28M	PEG	-	EPS next Q	-0.85	Inst Own	57.91%	Short Float	12.43%	Perf Quarter	-16.41%
Income	1.09B	P/S	0.32	EPS this Y	-	Inst Trans	11.05%	Short Ratio	3.96	Perf Half Y	-27.84%
Sales	732.24M	P/B	0.72	EPS next Y	-	ROA	141.98%	Short Interest	1.24M	Perf YTD	-20.52%
Book/sh	32.34	P/C	1.31	EPS next 5Y	-	ROE	-	52W High	46.95 -50.54%	Perf Year	-
Cash/sh	17.78	P/FCF	-	EPS past 3/5Y	- -	ROIC	137.47%	52W Low	18.00 29.00%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	3.27	Sales past 3/5Y	-13.46% -11.07%	Gross Margin	68.26%	Volatility	6.91% 7.28%	Perf 5Y	-
Dividend TTM	-	EV/Sales	0.71	EPS Y/Y TTM	2048.03%	Oper. Margin	14.99%	ATR (14)	1.85	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.65	Sales Y/Y TTM	-9.32%	Profit Margin	148.44%	RSI (14)	48.36	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	1.65	EPS Q/Q	-894.15%	SMA20	5.75%	Beta	-	Target Price	46.17
Payout	-	Debt/Eq	1.45	Sales Q/Q	-10.78%	SMA50	-9.24%	Rel Volume	0.52	Prev Close	23.00
Employees	3700	LT Debt/Eq	1.45	Earnings	Nov 06 BMO	SMA200	-22.39%	Avg Volume	312.63K	Price	23.22
IPO	Jun 30, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1229.41% 6.64%	Trades		Volume	162,352	Change	0.96%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-25	Initiated	CJS Securities	Market Perform

Feb-11-26 06:02AM	Amazon Pharmacy to expand same-day delivery to about 4,500 US cities and towns (Reuters)
Feb-10-26 09:00AM	Weight Watchers Partners with PVOLVE to Deliver Clinically Validated Strength Workouts to Members in the GLP-1 Era (GlobeNewswire)
Feb-09-26 04:28PM	Hims & Hers Stock Plunges 16%. Its Weight-Loss Drug Strategy Backfired. (Barrons.com) +10.92%
Feb-02-26 11:37PM	3 Out-of-Favor Stocks We Steer Clear Of (StockStory)
Jan-23-26 09:12AM	Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record (Benzinga)
03:46PM	Loading…
Jan-15-26 03:46PM	Why WeightWatchers (WW) Shares Are Sliding Today (StockStory) -8.88%
11:51AM	Half of GLP-1 users ditch their injections - and some are turning to other weight-loss methods instead (MarketWatch)
Jan-09-26 02:45PM	Novo Nordisk Is Getting a Major Boost from Amazon for Its New Wegovy Pill. Does That Make NVO Stock a Buy Here? (Barchart) -11.62%
10:07AM	Here's Why WeightWatchers (WW) Rose in Q4 (Insider Monkey)
Jan-07-26 05:00PM	'Women deserve an apology': For menopause, hormone therapy is now considered safe - just in time for aging millennials (MarketWatch)
09:00AM	Weight Watchers to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-05-26 08:42AM	Novo Nordisks Wegovy Pill Now Broadly Available Across U.S. (The Wall Street Journal)
08:05AM	Weight Watchers Expands Its Integrated GLP-1 Platform with Access to Wegovy Pill Advancing a New Standard for Long-Term Weight Health (GlobeNewswire)
Jan-04-26 11:42PM	3 Cash-Producing Stocks Walking a Fine Line (StockStory)
Dec-23-25 03:50PM	WeightWatchers (WW) Shares Skyrocket, What You Need To Know (StockStory) +14.18%
11:31PM	Loading…
Dec-18-25 11:31PM	3 Stocks Under $50 We Think Twice About (StockStory)
04:49PM	Weight Watchers Is Going All In on GLP-1 Drugs. Should You Buy WW Stock Here? (Barchart)
Dec-17-25 04:00AM	WeightWatchers revamps brand identity to better tap into GLP-1 craze (Marketing Dive)
Dec-16-25 09:05AM	Weight Watchers Launches a Fully Integrated Platform for the GLP-1 Era (GlobeNewswire) +12.13%
Dec-04-25 04:55PM	Why WeightWatchers (WW) Stock Is Trading Lower Today (StockStory) -6.98%
Nov-21-25 05:40PM	WeightWatchers, Opendoor, VF Corp, United Parks & Resorts, and Offerpad Shares Are Soaring, What You Need To Know (StockStory) +16.28%
Nov-13-25 11:39PM	3 Cash-Producing Stocks We're Skeptical Of (StockStory)
03:26PM	Meta Platforms Is Giving HubSpot Stock a Giant AI Boost. Will It Help Save HUBS? (Barchart)
Nov-06-25 11:37AM	Why Are WeightWatchers (WW) Shares Soaring Today (StockStory)
07:54AM	WeightWatchers's (NASDAQ:WW) Q3: Beats On Revenue, Stock Soars (StockStory)
07:00AM	WeightWatchers Announces Third Quarter 2025 Results (GlobeNewswire)
Nov-04-25 10:08PM	WeightWatchers (WW) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory) -8.90% +6.99%
02:10PM	WeightWatchers, Figs, Peloton, Levi's, and Gray Television Shares Are Falling, What You Need To Know (StockStory)
Oct-30-25 09:00AM	WeightWatchers Schedules Third Quarter 2025 Earnings Conference Call (GlobeNewswire)
Oct-22-25 12:33AM	1 Small-Cap Stock with Exciting Potential and 2 We Turn Down (StockStory)
05:25PM	Loading…
Oct-20-25 05:25PM	WeightWatchers (WW) Stock Trades Up, Here Is Why (StockStory) +9.25%
06:30AM	WeightWatchers Collaborates With Amazon Pharmacy to Increase Medication Delivery Speed, Convenience and Savings For Members (GlobeNewswire)
Oct-17-25 09:10AM	WeightWatchers Launches RxFlexFund, a New Employer Model for Expanding GLP-1 Coverage (GlobeNewswire) -7.92%
Oct-15-25 11:05AM	WeightWatchers for Business Annual Report Shows Breakthrough Weight Loss Results and Health Outcomes (GlobeNewswire) +12.08%
Oct-14-25 07:23AM	WW International (WW) Declined in Q3. Here's Why (Insider Monkey)
03:40AM	Zacks.com featured highlights include WW International and Webull (Zacks)
Oct-13-25 01:09PM	2 Stocks in Focus as New Analyst Initiates Coverage (Zacks)
Oct-05-25 11:36PM	Q2 Earnings Roundup: WeightWatchers (NASDAQ:WW) And The Rest Of The Specialized Consumer Services Segment (StockStory)
Oct-02-25 11:34PM	Spotting Winners: WeightWatchers (NASDAQ:WW) And Specialized Consumer Services Stocks In Q2 (StockStory)
Oct-01-25 10:55AM	Kevin Harts VC firm leads $35M Series B for weight-loss app Simple (TechCrunch) -5.26%
Sep-17-25 04:11PM	WeightWatchers (WW) Stock Trades Up, Here Is Why (StockStory)
Sep-09-25 11:30AM	WeightWatchers (WW) Shares Skyrocket, What You Need To Know (StockStory)
Sep-08-25 02:26PM	Why Is WeightWatchers (WW) Stock Soaring Today (StockStory) +5.51%
08:54AM	Queen Latifah Named Spokeswoman as WeightWatchers Launches First Comprehensive Menopause Programme (GlobeNewswire)
08:50AM	Queen Latifah Named Spokeswoman as WeightWatchers Launches First Comprehensive Menopause Program (GlobeNewswire)
08:00AM	WeightWatchers Attempts Comeback With Menopause Treatments and Steamy Ads (The Wall Street Journal)
Sep-03-25 04:00AM	WeightWatchers Advances International Growth With Strategic Leadership Appointment (GlobeNewswire)
Aug-18-25 01:32AM	The 5 Most Interesting Analyst Questions From WeightWatchers's Q2 Earnings Call (StockStory)
Aug-12-25 10:00AM	WeightWatchers Launches Inaugural Awards, Honoring Top Picks in Health and Wellness Products (GlobeNewswire)
12:00AM	The Latest Beauty Executive Moves at Estée Lauder, Neom Wellbeing and More (WWD)
Aug-11-25 01:34PM	WeightWatchers shuns compounded semaglutide amid FDA rules (Pharmaceutical Technology) -12.27%
11:40AM	WW Q2 Deep Dive: Strategic Restructuring and GLP-1 Headwinds Shape Outlook (StockStory)
09:50AM	WeightWatchers' stock leaps as weight-loss-drug subscriptions boost revenue (MarketWatch)
07:32AM	WeightWatchers's (NASDAQ:WW) Q2 Sales Top Estimates (StockStory)
07:00AM	WeightWatchers Announces Second Quarter 2025 Results (GlobeNewswire)
05:18AM	Barrick Mining headlines earnings slate (MarketWatch)
04:56AM	Stock Market Today: S&P 500 and Nasdaq eye fresh record highs, Dow to gain, as traders await crucial inflation data this week; Nvidia and AMD slip on reports of China export payments. (MarketWatch)
Aug-10-25 03:33PM	Everyones worried about the economy, but executives have been talking less about a recession (MarketWatch)
Aug-09-25 11:02PM	Earnings To Watch: WeightWatchers (WW) Reports Q1 Results Tomorrow (StockStory)
Aug-08-25 09:19AM	WW International Inc (WW) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-07-25 10:58AM	WeightWatchers Appoints SoulCycle Co-Founder Julie Rice as Chief Experience Officer to Lead Community and Brand Innovation (GlobeNewswire) -7.40%
09:34AM	Exclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers (Fortune)
Aug-05-25 03:50PM	Why WeightWatchers (WW) Shares Are Falling Today (StockStory) -7.22%
Aug-04-25 05:38PM	WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence (GlobeNewswire)
09:28AM	What To Expect From WW International Inc (WW) Q2 2025 Earnings (GuruFocus.com)
Aug-03-25 11:06PM	WeightWatchers (WW) Q1 Earnings: What To Expect (StockStory)
Jul-30-25 04:05PM	WeightWatchers Schedules Second Quarter 2025 Earnings Conference Call (GlobeNewswire) +7.55%
Jul-21-25 11:34PM	Q4 Earnings Outperformers: WeightWatchers (NASDAQ:WW) And The Rest Of The Specialized Consumer Services Stocks (StockStory) +7.37%
Jul-17-25 11:34PM	A Look Back at Specialized Consumer Services Stocks' Q4 Earnings: WeightWatchers (NASDAQ:WW) Vs The Rest Of The Pack (StockStory)
Jul-16-25 12:11PM	WeightWatchers (WW) Stock Trades Up, Here Is Why (StockStory)
Jul-08-25 04:27PM	Revived WeightWatchers Rallies, In 'Strongest Position In Years' (Investor's Business Daily)
09:31AM	Circle initiated, CoreWeave downgraded: Wall Street's top analyst calls (The Fly)
08:22AM	WeightWatchers emerges from bankruptcy, and is taking aim at menopause (MarketWatch)
06:30AM	WeightWatchers Completes Financial Reorganization, Strengthens Leadership, and Expands Program Innovation to Support Women Through Menopause (GlobeNewswire)
Jun-26-25 12:19PM	Micron slips, Meta & AI talent, Novo Nordisk & Weight Watchers (Yahoo Finance Video)

WW International, Inc. engages in the provision of weight management services. It operates through the following geographical segments: United States, Germany, and Other. The company was founded by Jean Nidetch in 1963 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hawks Carney	Director	Nov 19 '25	Buy	22.14	29,057	643,464	29,057	Nov 20 04:01 PM
Haag Nicole	Corp Controller Prin Acct Off	Aug 18 '25	Sale	30.86	469	14,475	0	Aug 20 04:01 PM

LXRX

Lexicon Pharmaceuticals Inc

WW

WW International Inc

Upgrade your FINVIZ experience